C Santos, G R Rodrigues, L F Lima, M C G Dos Reis, N B Cunha, S C Dias, O L Franco
S-Inova Biotech, Programa de Pós-Graduação Em Biotecnologia, Universidade Católica Dom Bosco (UCDB), Campo Grande, Brazil.
Centro de Análises Proteômicas e Bioquímica (CAPB), Programa de Pós-Graduação Em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília (UCB), Brasília, Brazil.
Front Bioeng Biotechnol. 2022 Dec 12;10:1051456. doi: 10.3389/fbioe.2022.1051456. eCollection 2022.
Antimicrobial peptides (AMPs) have shown cell membrane-directed mechanisms of action. This specificity can be effective against infectious agents that have acquired resistance to conventional drugs. The AMPs' membrane-specificity and their great potential to combat resistant microbes has brought hope to the medical/therapeutic scene. The high death rate worldwide due to antimicrobial resistance (AMR) has pushed forward the search for new molecules and product developments, mainly antibiotics. In the current scenario, other strategies including the association of two or more drugs have contributed to the treatment of difficult-to-treat infectious diseases, above all, those caused by bacteria. In this context, the synergistic action of AMPs associated with current antibiotic therapy can bring important results for the production of new and effective drugs to overcome AMR. This review presents the advances obtained in the last 5 years in medical/antibiotic therapy, with the use of products based on AMPs, as well as perspectives on the potentialized effects of current drugs combined with AMPs for the treatment of bacterial infectious diseases.
抗菌肽(AMPs)已显示出针对细胞膜的作用机制。这种特异性可有效对抗对传统药物产生耐药性的感染因子。AMPs的膜特异性及其对抗耐药微生物的巨大潜力给医学/治疗领域带来了希望。全球范围内因抗菌药物耐药性(AMR)导致的高死亡率推动了对新分子和产品开发的探索,主要是抗生素。在当前情况下,包括联合使用两种或更多药物在内的其他策略有助于治疗难治性传染病,尤其是由细菌引起的疾病。在此背景下,AMPs与当前抗生素疗法的协同作用可为生产克服AMR的新型有效药物带来重要成果。本综述介绍了过去5年在医学/抗生素治疗方面取得的进展,包括使用基于AMPs的产品,以及当前药物与AMPs联合治疗细菌感染性疾病的潜在效果展望。